The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 ...
Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.
At close: April 4 at 4:00:01 PM EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback